PT - JOURNAL ARTICLE AU - Andreas Vosseler AU - Jürgen Machann AU - Louise Fritsche AU - Christian Kübler AU - Hans-Ulrich Häring AU - Andreas L. Birkenfeld AU - Norbert Stefan AU - Andreas Peter AU - Andreas Fritsche AU - Robert Wagner AU - Martin Heni TI - Interscapular fat is associated with impaired glucose tolerance and insulin resistance independent of visceral fat mass AID - 10.1101/2022.02.07.22270571 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.07.22270571 4099 - http://medrxiv.org/content/early/2022/02/07/2022.02.07.22270571.short 4100 - http://medrxiv.org/content/early/2022/02/07/2022.02.07.22270571.full AB - Dysregulated body fat distribution is a major determinant of various diseases. Adipose tissue in different localizations of the body appear to have protective or detrimental properties. Particularly increased visceral fat mass and ectopic lipids in the liver are linked to metabolic disorders such as insulin resistance and type 2 diabetes. Furthermore, interscapular fat is considered to be a non-classical, but metabolically active, fat compartment.In this study, we measured interscapular fat mass and investigated its relationship with glucose tolerance, insulin sensitivity and insulin secretion in 822 subjects with a wide range of body mass index (BMI) and different glucose tolerance status. Magnetic resonance imaging was used to quantify body fat depots and an oral glucose tolerance test (OGTT) was performed to determine glucose metabolism.Elevated interscapular fat mass was positively associated with age, BMI, total body, visceral and subcutaneous adipose tissue mass. High interscapular fat mass associated with elevated fasting glucose levels, glucose levels at 2 hours during the OGTT, glycated hemoglobin, as well as with insulin resistance, independently of sex, age, total body and visceral fat mass.In conclusion, interscapular fat might be a highly specific fat compartment with potential impact on glucose metabolism and the pathogenesis of diabetes mellitus. Since this depot is assessible by ultrasound, it could represent a feasible target to quantify metabolic risk in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported in parts by a grant (01GI0925) from the Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD). We acknowledge support by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publishing Fund of the University of Tuebingen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University Hospital of Tuebingen, Germany, gave ethical approval for this work. Ethics committee ID 055/2012BO1.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available due to them containing information that could compromise research participant privacy/consent.